Amgen and Genentech Inc. have entered into license agreements granting licenses to each other under multiple patents relating to the manufacture and use of antibodies and related technology.

The agreements include a grant by Genentech to Amgen of a license for multiple antibodies under the Cabilly patent family relating in part to methods of producing immunoglobulins, states a company release.

Amgen discovers, develops and delivers innovative human therapeutics.

Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercialises bio-therapeutics for significant unmet medical needs.